For the Inventor, By the Inventor

Enter inventor name

Jiangmei Li

USPTO Granted Patents = 14 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 1 (Patent Applications = 11)

Average Co-Inventor Count = 3.4

ph-index = 2

Forward Citations = 9(Granted Patents)

Company Filing History:

Beijing Mabworks Biotech Co. Ltd.

Beijing Mabridge Biopharmaceutical Co., Ltd.

where one patent can have more than one assignee

Years Active: 2019-2024

Loading Chart...

Loading Chart...

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180280 - Antibodies binding human and monkey CD3 and uses thereof (2024-12-31),

2. 12084520 - Antibodies binding BCMA and CD3 and uses thereof (2024-09-10),

3. 11718674 - Antibodies binding PD-L1 and uses thereof (2023-08-08),

4. 11091558 - Anti-OX40 antibodies and uses thereof (2021-08-17),

5. 10946092 - Antibodies binding LAG3 and methods of treatment using them (2021-03-16),

6. 10662249 - Antibodies targeting CD40 and uses thereof (2020-05-26),

7. 10654939 - Antibodies specific to CD40 and uses thereof (2020-05-19),

8. 10654938 - CD40 binding antibodies and uses thereof (2020-05-19),

9. 10654937 - CD40 specific antibodies and uses thereof (2020-05-19),

10. 10647776 - Anti-CD40 antibodies and uses thereof (2020-05-12),

11. 10577424 - Antibodies binding VISTA and uses thereof (2020-03-03),

12. 10570210 - Antibodies binding CD40 and uses thereof (2020-02-25),

13. 10442866 - Antibodies binding OX40 and uses thereof (2019-10-15),

14. 10421817 - Antibodies binding human Claudin 18.2 and uses thereof (2019-09-24),

Title: Jiangmei Li: Innovator in Monoclonal Antibody Development

Introduction

Jiangmei Li is a prominent inventor based in Beijing, China, known for his significant contributions to the field of biopharmaceuticals. He holds a total of 14 patents, showcasing his innovative work in monoclonal antibodies and their applications in treating various diseases.

Latest Patents

Among his latest patents, Jiangmei Li has developed antibodies that bind to human and monkey CD3, which are crucial for treating inflammatory diseases and preparing bispecific antibodies. One of his notable inventions includes a bispecific antibody targeting CD3 and CD20, which has potential applications in cancer treatment. Additionally, he has created antibodies that specifically bind to BCMA and CD3, aimed at treating cancers such as multiple myeloma and addressing inflammatory and autoimmune diseases.

Career Highlights

Jiangmei Li has worked with several reputable companies in the biopharmaceutical sector, including Beijing Mabworks Biotech Co. Ltd. and Beijing Mabridge Biopharmaceutical Co., Ltd. His expertise in monoclonal antibody development has positioned him as a key player in advancing therapeutic options for patients.

Collaborations

Throughout his career, Jiangmei Li has collaborated with notable colleagues, including Feng Li and Wenqi Hu, contributing to the advancement of innovative biopharmaceutical solutions.

Conclusion

Jiangmei Li's work in the field of monoclonal antibodies has made a significant impact on the treatment of various diseases, particularly in oncology and immunology. His innovative spirit and dedication to research continue to drive advancements in biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…